Skip to main content
Top
Published in: International Journal of Clinical Oncology 6/2016

01-12-2016 | Original Article

High incidence of urological complications in men dying from prostate cancer

Authors: Takashi Kobayashi, Tomomi Kamba, Naoki Terada, Toshinari Yamasaki, Takahiro Inoue, Osamu Ogawa

Published in: International Journal of Clinical Oncology | Issue 6/2016

Login to get access

Abstract

Background

The incidence and clinical characteristics of urological adverse events suffered by patients with lethal prostate cancer (PCa) toward the end of life are not fully understood.

Methods

A search of our hospital medical registry identified 3816 individuals diagnosed with PCa, among whom 243 died from the disease and 144 died from other causes (n = 387). We retrospectively reviewed the 387 patients who had died to determine the incidence of PCa-related urological complications, associated factors, and subsequent palliative interventions.

Results

Major urological complications that required therapeutic intervention were observed in 28.4 % of PCa patients dying from the disease itself, whereas such complications were much less frequent (4.3 %) in PCa patients dying from other causes. Urological complications were associated with local recurrence in men who underwent prostatectomy, lower irradiation dose in men who underwent radiotherapy, and pretreatment higher T stage and absence of metastasis in men who underwent androgen deprivation therapy (ADT) as the primary treatment. Patients who received long-term ADT for localized disease had the highest risk for urological complications. Therapeutic intervention was highly effective for palliation.

Conclusion

Urological adverse events are very common in PCa patients who are dying from the disease. Prevention or early palliation should be considered in patients at high risk of PCa-related urological complications.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefPubMed
2.
go back to reference Litwin MS, Lubeck DP, Stoddard ML et al (2001) Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol 165:871–875CrossRefPubMed Litwin MS, Lubeck DP, Stoddard ML et al (2001) Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol 165:871–875CrossRefPubMed
3.
go back to reference Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467–479CrossRefPubMed Heidenreich A, Bastian PJ, Bellmunt J et al (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65:467–479CrossRefPubMed
4.
go back to reference Anast JW, Andriole GL, Grubb RL 2nd (2007) Managing the local complications of locally advanced prostate cancer. Curr Urol Rep 8:211–216CrossRefPubMed Anast JW, Andriole GL, Grubb RL 2nd (2007) Managing the local complications of locally advanced prostate cancer. Curr Urol Rep 8:211–216CrossRefPubMed
5.
go back to reference Crain DS, Amling CL, Kane CJ (2004) Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 171:668–671CrossRefPubMed Crain DS, Amling CL, Kane CJ (2004) Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol 171:668–671CrossRefPubMed
6.
go back to reference Din OS, Thanvi N, Ferguson CJ et al (2009) Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiother Oncol 93:192–196CrossRefPubMed Din OS, Thanvi N, Ferguson CJ et al (2009) Palliative prostate radiotherapy for symptomatic advanced prostate cancer. Radiother Oncol 93:192–196CrossRefPubMed
7.
go back to reference Won AC, Gurney H, Marx G et al (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 112:E250–E255CrossRefPubMed Won AC, Gurney H, Marx G et al (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 112:E250–E255CrossRefPubMed
8.
go back to reference Khafagy R, Shackley D, Samuel J et al (2007) Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med 10:705–711CrossRefPubMed Khafagy R, Shackley D, Samuel J et al (2007) Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med 10:705–711CrossRefPubMed
9.
go back to reference Spencer BA, Insel BJ, Hershman DL et al (2013) Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer. Support Care Cancer 21:1303–1311CrossRefPubMed Spencer BA, Insel BJ, Hershman DL et al (2013) Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer. Support Care Cancer 21:1303–1311CrossRefPubMed
10.
go back to reference Chiou RK, Chang WY, Horan JJ (1990) Ureteral obstruction associated with prostate cancer: the outcome after percutaneous nephrostomy. J Urol 143:957–959PubMed Chiou RK, Chang WY, Horan JJ (1990) Ureteral obstruction associated with prostate cancer: the outcome after percutaneous nephrostomy. J Urol 143:957–959PubMed
11.
go back to reference Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65:1058–1066CrossRefPubMed Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65:1058–1066CrossRefPubMed
13.
go back to reference Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed
14.
go back to reference Irwin KE, Greer JA, Khatib J et al (2013) Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival. Chron Respir Dis 10:35–47CrossRefPubMed Irwin KE, Greer JA, Khatib J et al (2013) Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival. Chron Respir Dis 10:35–47CrossRefPubMed
15.
go back to reference Mourmouris P, Efstathiou E, Papatsoris A (2013) Androgen deprivation therapy and cardiovascular risk. Nephrourol Mon 5:653–654CrossRefPubMed Mourmouris P, Efstathiou E, Papatsoris A (2013) Androgen deprivation therapy and cardiovascular risk. Nephrourol Mon 5:653–654CrossRefPubMed
Metadata
Title
High incidence of urological complications in men dying from prostate cancer
Authors
Takashi Kobayashi
Tomomi Kamba
Naoki Terada
Toshinari Yamasaki
Takahiro Inoue
Osamu Ogawa
Publication date
01-12-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 6/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0993-x

Other articles of this Issue 6/2016

International Journal of Clinical Oncology 6/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine